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Abstract
Background: Opioid abuse is a challenging health care concern, and has been identified as a
national public health issue. The prevalence of illicit fentanyl and prescription pain medication in
our society are related to a multitude of factors which have impacted many lives and triggered a
national epidemic despite experts' preventative measures and treatment recommendations.
Purpose: A quality improvement (QI) project was designed to enhance the assessment of
patients suffering from opioid use disorder (OUD) with evidence-based screening tools to
prevent opioid abuse among adult patients in a chronic care psychiatric hospital. Methods: The
QI project integrated an educational intervention to an interdisciplinary team comprising of
psychiatrists, psychologists, nurses, mental health counselors, and social workers. The project’s
purpose was to improve the process of opioid abuse evaluation for clients with co-occurring
mental illness and OUD at an inpatient psychiatric hospital. The DNP project included screening
scales to identify and monitor six clients receiving medication-assisted treatment (MAT) for
behavior change. A pre-intervention questionnaire and a post-test questionnaire were initiated at
the beginning prior to and following the presentation of education intervention, respectively, to
measure the knowledge gained. Results and Conclusion: The clinician participants reported
enhanced knowledge in assessment, identification, and referral of clients with OUD to specialty
treatment services. Additionally, the client participants demonstrated increased knowledge of
opioid abuse risk and the need to continue MAT after discharge.
Keywords: Opioid use disorder and co-occurring mental illness, medicated-assisted
treatment, opioid abuse prevention, opioid abuse assessment scale, transtheoretical model of
behavior change.
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A Quality Improvement Project for Opioid Use Disorder at a Psychiatric Hospital
in Western Massachusetts

Introduction
Problem and Purpose
Opioid use disorder (OUD) has been categorized as a public health emergency (Duber et
al., 2018). According to the National Institute of Health (NIH, 2019), drug abuse, opioid
dependence, and overdose related to abusing opioid prescriptions, heroin, and fentanyl have
prompted a national epidemic in the U.S. with over 130 deaths per day. The Centers for Disease
Control and Prevention (CDC, 2016) has published clinical practice guidelines to help in the
treatment and prevention of drug abuse and overdose.
Western Massachusetts has been identified by the Massachusetts Department of Public
Health as having the second-highest number of opioid-related deaths in the state of
Massachusetts. Opioid abuse in the general population and illegal prescription painkillers
(namely, fentanyl and heroin in the community where the hospital is situated) are the
overwhelming ecological influences. The public psychiatric hospital in western Massachusetts,
was the setting for the project and serves individuals with various mental illness diagnoses. In
addition to mental illness, the hospital had several episodes of clients overdose from illicit opioid
abuse and two deaths in 2019(Curran, 2019). Patients at the hospital are usually not screened
adequately with standardized opioid assessment scales during the admission evaluation.
Moreover, the issues of patients craving for illegal substances were not correctly addressed and
treated since most of the psychiatric clinicians did not have the authority to prescribe medication
assisted treatment for clients with opioid use disorder at that time. Subsequently, opioid abuse
persists at the project site because patients with this diagnosis are unaware of the problem.
Furthermore, some inpatient psychiatric facility clients with opioid addiction are ambivalent
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about engaging in the available treatment with psychotherapy intervention without access to
medication-assisted treatment during their hospitalization.
Medication-assisted treatment (MAT) utilizes medications such as buprenorphine,
naltrexone, and methadone, combined with psychotherapy interventions and counseling to treat
opioid use disorder (Substance Abuse and Mental Health Services Administration [SAMHSA],
2021). Medication-assisted treatment is predominantly utilized to treat clients challenged with
opioid abuse. The prescribed medication works to normalize brain chemistry, block the euphoric
effects of opioids, liberate physical cravings, and stabilize body functions by eliminating the
damaging elated effects of opioid abuse (SAMHSA, 2021). The evidence-based literature shows
that a combination of early assessment to identify clients with OUD, medication, and
psychotherapy intervention can be used to treat patients struggling with opioid use disorder
successfully (SAMHSA, 2021).
On the other hand, the implementation of MAT is currently fragmented in underserved
settings such as prisons and psychiatric hospitals. The gap between evidence-based information
and the translation of this knowledge into clinical practice to improve care for patients at risk in a
psychiatric hospital can be done by improving clinical skills through training. The educational
component of this QI project includes how to properly use opioid assessment tools such as
Screening, Brief Intervention, Referral to Treatment (SBIRT) and the Clinical Opiate
Withdrawal Scale (COWS) (Rosenthal et al., 2018). The CDC (2016) recommendation also
reveals that evidence-based practice should include counseling with motivational interviewing
skills, clinical judgment, and easy access to MAT for patients with opioid use disorder (OUD).
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Background
Opioid abuse disorder is prevalent among clients with a mental health condition. Han et al.
(2017) reported that about 7.7 million adults suffer from a co-occurring psychiatric diagnosis and
substance abuse in the U.S.and 38.4% of this population are ambivalent about engaging in
treatment. The National Institute on Drug Abuse (2020) reported data from a nationwide sample
that noted that people with mental illness were at increased risk for ingesting nonmedical
prescription opioids. The interactions between psychiatric diagnoses and opioid abuse can
exacerbate the symptoms of both disorders and predispose clients to the risk of overdose and
subsequent death from opioids (Han et al., 2017). Besides, Velez et al. (2016) concluded that
inpatient hospitalization is an appropriate timeframe to successfully reach patients who are
indicated for substance abuse treatment, as they may comprehend that substance abuse has
harmfully affected their wellbeing. The US Preventative Service Task Force [USPSTF] (2019)
recommends OUD treatment, which involves assessing illicit drugs and the misuse of
prescription drugs and subsequent referral for intervention to counteract drug abuse.
The Clinical Opiate Withdrawal Scale (COWS) is an 11-item tool designated for
implementation by healthcare practitioners to assess and monitor signs and symptoms of opiate
withdrawal in inpatient and outpatient settings (Tompkins et al., 2009). Several studies recognize
the COWS as reliable (Wesson & Ling, 2003). Also, the Screening, Brief Intervention, and
Referral to Treatment (SBIRT) tool is designed to provide early intervention and treatment for
individuals diagnosed with substance abuse or clients at risk of displaying OUD (SAMHSA,
2017). The approach utilizes procedures that assess and classify substance abuse, offer
motivational interviewing techniques through counseling to enhance the client's insight into
opioid abuse, and refer clients with OUD to extensive specialty treatment (SAMHSA, 2017).
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Problem Statement
The opioid abuse epidemic has impacted society and resulted in drug overdose deaths
reaching 63,632 in 2016, which is an estimated increase of 21.4% from the previous year (Duber
et al., 2018). Also, Duber et al. reported that 66.4% of users died from illegal opioid abuse
events, which represents an alarming annual increasing rate of 27.7% from 2015. Subsequently,
Vashishtha et al. (2017) stated that the drug overdose death rate has exceeded the motor vehicle
accidental death rate and the researchers classify drug overdose as the highest avoidable cause of
death in America. Evidence from the literature supports a multifaceted intervention that includes
early assessment for the misuse of illicit opioids and a subsequent recommendation for treatment
that provides MAT, psychotherapy, and individual counseling (CDC, 2016; Duber et al., 2018;
SAMHSA, 2021; USPSTF, 2019).
Evidence-based findings from the literature endorse the appropriate use of opioid
assessment screening scales like COWS and SBIRT to identify and refer patients with OUD to
treatment (Rosenthal et al., 2018; Timko et al., 2016; Vashishtha et al., 2017). The primary focus
of the Doctoral Nurse Practitioner (DNP) capstone project was to provide education for
healthcare clinicians regarding how to appropriately use standardized screening opioid
assessment scales in identifying patients with OUD before referring these patients for treatment
that incorporates MAT with psychotherapy intervention. The goal of this kind of treatment is to
decrease opioid abuse and overdoses within the psychiatric healthcare facility and inspire change
in these clients.
Review of the Literature
A comprehensive search of the literature on opioid abuse and opioid use disorder to obtain
evidence for the review was initiated through the National Institute of Health [NIH], National
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Library of Medicine website to retrieve applicable medical subject headings [MeSH] terms. The
MeSH terms of opioid abuse/dependence, opioid overdose, and co-occurring psychiatric
symptoms were applied to the Cumulative Index of Nursing and Allied Health Literature
[CINAHL], PsycINFO, and MEDLINE databases. The following inclusive limiting filters were
applied: (a) peer-reviewed English language research literature published from 2015 to 2019 and
(b) randomized controlled trials. The search was unsuccessful and yielded three articles that did
not meet the criteria of the search terms.
Subsequently, after consultation with the librarian at the University of Massachusetts
Amherst Graduate Research Center, the MeSH term was paraphrased to opioid abuse and
treatment intervention. The Cochrane Library was also used to simplify the search terms. The
simplified MeSH terms were reapplied to CINAHL and PubMed of the National Library of
Medicine separately. As a result, 167 articles were retrieved. Inclusion filters that consisted of
free full-text research articles published in the English language within the past five years were
utilized to reduce the number of articles to 20. At this point, the exclusion filters used were sex,
geographic subset, publication type, a particular interest, and pregnancy. Other subjects such as
HIV, Hepatitis C, co-occurring medical diagnoses, polysubstance abuse, and alcohol use disorder
were excluded from the review. Of the 20 study articles identified in the search results, ten
centered on opioid abuse and met the criteria for inclusion in the assessment of the literature.
Synthesis of the Key Concepts of the Literature
The ten articles selected for the literature review consisted of two systematic reviews, one
quasi-experimental non-randomized study, two non-experimental design studies, one quantitative
randomized controlled trial (RCT), one QI study, and two expert opinion articles. In addition,
this literature review included a concise assessment of the CDC’s (2016) clinical practice
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guideline for prescribing opioids for chronic pain in outpatient settings. The following is a
description of the significant results from these research findings.
A study by Baird et al. (2019) assessed a safer opioid prescribing procedure for patients
being released from a trauma service center. This quasi-experimental study examined safety
concerns surrounding opioid prescribing for patients at risk of opioid abuse and overdose. They
reviewed the electronic health records of two different trauma centers from 2014 to 2016 with a
sample size of 191 (pre-intervention application) and 316 (post-intervention implementation) to
identify patients at risk for opioid abuse. This research demonstrated that clinicians could
identify best practice alerts to trigger naloxone prescriptions for patients at risk of opioid abuse.
The findings also initiated opioid prescribing criteria within the trauma centers (Baird et al.,
2019).
Ronan and Herzig (2016) surveyed patient discharge records from 2002 to 2012 in the
U.S.to determine the rate of hospitalization, infections associated with OUD, cost of treatment,
and mortality rates among patients with OUD. The authors revealed that hospitalization and the
cost of providing care for clients with OUD have significantly increased since 2002 with the
government bearing the financial burden of cost. Bowles and Lankenau (2018) investigated
opioid distribution methods in an opioid program tailored to educate and provide naloxone to
patients with OUD to prevent overdose from opioids. The study has a significant implication
regarding how to avoid injury and promote healthy behaviors among patients with OUD.
However, the limitations of the research, such as its small sample size, bias, methods of data
collection, and analysis, may have compromised the validity and confirmability of the results
(Bowles & Lankenau, 2018).
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Wasan et al. (2015) explored how psychiatric symptoms that produce adverse effects such
as depression and anxiety can predict patients at risk of an OUD, especially for a patient on
opioid treatment for chronic lower back pain (CLBP) as compared with a patient without
psychiatric symptoms. Wasan et al. (2015) demonstrated that adverse effects such as depression
and anxiety related to co-occurring mental illness diagnoses of depression and anxiety disorder
are strong predictors of a poor treatment result with an opioid for patients with CLBP and a risk
factor for opioid abuse.
Rosenthal et al. (2018) identified a gap in knowledge regarding how to appropriately
utilize the SBIRT opiate assessment tool and the COWS to evaluate clients with OUD. The study
describes the wrong ways SBIRT and COWS have been used and the vulnerability showed by
nurses in an inpatient facility before implementing a quality improvement project to train
clinicians on how to use these assessment tools to identify patients with OUD and those with
opiate withdrawal symptoms (Rosenthal et al., 2018).
Timko et al. (2016) systematically reviewed and compared 55 studies on MAT therapy
using buprenorphine, naltrexone, methadone, and behavioral treatment. The research report
unfolded different rates of retention in the MAT program. The investigation of a MAT study
from 2010 to 2014 by the authors revealed that patients with OUD could be clinically "managed
to increase their retention in MAT and ultimately improve their quality of life" (Timko et al.,
2016, p. 9).
Duber et al. (2018) found that eight million Americans, which represents an estimated 1.4
percent of the national census aged 12 and older, abuse pain relievers. They also found that
329,000 individuals aged 12 and above abuse heroin. Furthermore, in their systematic review,
they reported that 2.1 million Americans abuse prescription opioids and approximately 135,000
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were recorded as having initiated heroin abuse in 2015. Consequently, the researchers examined
assessment tools such as the brief self-report tool with yes or no questions and the 5-point Likert
scale used for OUD assessment and explored the prescription drug monitoring program (PDMP)
to rule out drug-drug interaction. The study suggested strategies to treat patients withdrawing
from opioids and identified MAT therapy as the treatment of choice for OUD patients in acute
and chronic settings (Duber et al., 2018).
Vashishtha et al. (2017) clearly described the global crisis of OUD and the implication for
infectious diseases such as HIV/AIDs. The authors identified factors that impede the
accessibility of MAT therapy to patients with OUD as follows: financial cost, lack of
accessibility of MAT, and other systemic and environmental policies such as compliance with
federal methadone laws, rigorous criteria for clinicians with prescriptive rights to obtain MAT
certification waivers, a sidelined population, the stigma associated with OUD that prevents
clients from engaging in treatment, lack of national health insurance, long waitlist, lack of
integrated treatment center, very few addiction experts, and lack of federal and state funding for
MAT therapy. The authors succinctly recommended the following: adequate government
funding for treatment, the removal of barriers that impede healthcare providers from making
MAT therapy available to patients with OUD, availability of programs or centers for MAT
treatment in opioid-infested communities and neighborhoods, and the formulation of policies that
legalize drug possession to enable OUD patients present from hideouts and engage in treatment
to prevent HIV/AIDs (Vashishtha et al., 2017).
The developers of the CDC (2016) guideline revealed that opioids are not endorsed as an
initial treatment for chronic pain for adults in outpatient settings and advised clinicians to use
non-pharmacologic and non-opioid therapy in providing care for chronic pain for adult patients
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in outpatient settings. The CDC (2016) opioid prescribing guideline specified criteria for using
assessment tools and clinical judgment to evaluate clients at risk for opioid use disorder and
prevent adverse events of opioid abuse and overdose. The guidelines advised clinicians to
prescribe naloxone and opioids for patients with substance abuse history and refer clients with
OUD for MAT.
In conclusion, the literature review reveals the magnitude of the opioid abuse crisis. The
literature provided evidence to support the proposed intervention. Additionally, these findings
describe various strategies to tackle the opioid abuse crisis by following evidence-based
recommendations that include the appropriate utilization of opioid assessment tools such as the
SBIRT and COWS to identify and refer patients withdrawing from opioids for treatment, as well
as through clinical judgment of experts. They strongly endorse medication-assisted treatment
therapy as the treatment of choice for a patient suffering from OUD (CDC, 2016; Rosenthal et
al., 2018; Timko et al., 2016; Vashishtha et al., 2017).
In addition, the literature review identified and revealed barriers to implementing MAT
therapy, such as systemic barriers, access to MAT therapy, and insurance cost (Vashishtha et al.,
2017). The evidence from the literature shows that clinicians should prescribe naloxone with
opioids for patients at risk of OUD to mitigate the risk of overdose from opioids (Baird et al.,
2019; CDC, 2016; Ronan & Herzig, 2016). The evidence from the literature also reveals that
clinicians should treat other psychiatric symptoms with psychoactive medications and use nonopioid analgesics to treat patients with CLBP who have a co-occurring psychiatric disorder. This
is because the negative effects that originate from psychiatric disorders such as depression and
anxiety will produce poor outcomes with opioid treatment and predispose patients in this
population to abuse opioids (CDC, 2016; Wasan et al., 2015). These recommendations provide
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clinicians with some resources and means to use in response to the opioid epidemic crisis in
America.
Theoretical Framework/Evidence-Based Practice Model
The conceptual framework underpinning the QI project is the transtheoretical behavioral
change model (TTM) initially posited by Prochaska and DiClemente in 1982 (Appendix A).
Prochaska et al. (1992) noted that people intentionally change and summarize the key
components of the transtheoretical processes of change into pre-contemplation, contemplation,
preparation, action, maintenance, and termination. This outline of the stages of change was
detected in research with smokers trying to relinquish their own habit and smokers in specialized
management programs. The authors noted that individuals were observed as advancing linearly
from the stage of pre-contemplation to the stages of contemplation, preparation, action, and
maintenance, and termination.
According to Prochaska et al. (1992), the pre-contemplation stage in the trajectory of the
change spectrum is the stage at which the individual has no plan to change his/her behavior in
the immediate future. The individuals at this stage are grossly unaware of the need to change
their habits, and they do not consider the behavior problematic. On the other hand, the
researchers stated that contemplation is the phase in which individuals are mindful that difficulty
in their behavior exists and are sincerely thinking about conquering it but have not yet dedicated
themselves to take a responsible plan of action to overcome the problem. At this stage,
individuals evaluate the pros and cons of the challenge and the solution to the difficulty
(Prochaska et al., 1992). The authors described the preparation stage as the stage that merges
purpose with behavior norms. In the preparation stage, the individual plans to act soon and may
have worked toward taking the action and failed. People in this phase are experiencing and
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expressing small positive changes (Prochaska et al., 1992). The action stage is when individuals
adjust their conduct, practices, situation, and background to change the difficulties. In the action
phase, the individual is committed to the change process and is taking positive steps in this
direction.
The writers stated that maintenance is when individuals act to prevent setbacks and
strengthen the benefits accomplished in the action phase and successfully terminate the behavior
(Prochaska et al., 1992). The TTM demonstrates an understanding of when shifts in opinions,
objectives, and performances occur. Thus, the TTM was utilized in this QI project because it
involves screening modalities that identify adults with opioid abuse disorder in a chronic care
psychiatric hospital. It also entails measures that encourage adults with OUD to change from
abusing illegal opioids to abstaining from this behavior. The change process was initiated and
accomplished in adults diagnosed with opioid abuse by the psychiatrist, psychiatric mental health
nurses, clinical nurse specialists, social workers, psychologists, and registered nurses. The
COWS and SBIRT assessment tools were the basis of the assessment of clients with opioid use
disorder and early referral to treatment to prevent opioid abuse and accidental deaths.
Methods
The quality improvement (QI) project design consisted of an educational intervention to
16 healthcare providers in order to increase knowledge, skills, and confidence levels in assessing,
identifying and treating those with dual diagnosis in a public inpatient psychiatry hospital. Data
was collected by the DNP student through pre, and posttest surveys created by the DNP student.
Literature substantiates using the Clinical Opiate Withdrawal Scale (COWS) and the Screening,
Brief Intervention, and Referral to Treatment (SBIRT) scale in assessing, identifying and
referring clients with opioid use disorder (OUD) to medication-assisted treatment, counseling
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and a substance awareness group. The QI project provided an educational PowerPoint training to
the participants prior to implementing the screening scales. Furthermore, the QI intervention also
utilized the transtheoretical model of behavior change (TTM) to measure behavior change in six
clients (Prochaska and DiClemente, 1982). The clients were selected by their clinicians as
exhibiting a diagnosis of opioid use disorder (OUD) based on DSM-V criteria. To measure the
outcome of this DNP project, the following instruments were utilized: a pre-test questionnaire
and a post-test intervention survey which was administered following a presentation on OUD
signs and symptoms, screening scales and treatment.
Goals, Objectives, and Expected Outcomes
The overarching goal of the project was to provide education to healthcare clinicians
concerning how to appropriately use standardized screening opioid assessment scales to identify
patients with co-occurring OUD, offer brief intervention, and refer the patients for treatment in
order to decrease opioid abuse and overdose within the psychiatric facility and inspire change in
these clients. The treatment included medication-assisted treatment (MAT), individual
counseling that incorporates motivational interviewing strategies and substance awareness group.
The goals, of the QI project were as follows:
Goal 1. The interdisciplinary team clinicians on Wards A2 and C3 of the psychiatric hospital
were able to gain knowledge in OUD signs, symptoms, assessment, and identification and in the
referral of clients to treatment with medication-assisted therapy, a substance awareness group,
and individual counseling.
Goal 2. The psychiatry clinicians were able to verbalize that client benefitted from MAT, the
substance awareness group, and individual counseling.
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Expected Outcome: The QI project implementation resulted in increased awareness among the
participants of the signs and symptoms of OUD, screening scales, early diagnosis, and the
treatment of clients as evidenced by positive self-report from data yielded from the completion of
the survey and interviews.
Population and Project Site
The project was implemented on an inpatient public psychiatric hospital in a small town in
western Massachusetts. The hospital provides acute and chronic psychiatric services to over 260
adults and 60 teenagers with severe mental and emotional disorders. The patients come from
various backgrounds and cultures. The services provided comprise psychiatric evaluation and
treatment, psychotherapy intervention, forensic evaluation, and clients' commitment through the
courts for treatment. In addition, substance abuse treatment with buprenorphine, methadone, and
naltrexone is also offered and was added earlier this year after several occurrences of opioid
abuse and overdose in the hospital. The project site also coordinates with other facilities to offer
electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), medical assessment,
and treatment for clients in need of such services.
The healthcare providers on the two units include 3 psychiatrists, two on-call psychiatrists,
and several psychiatric interns as well as a medical doctor during off-hours, three clinical nurse
specialists, 6 licensed social workers, 2 psychologists, two licensed mental health counselors, 6
occupational/rehabilitation therapists, several administrators, and numerous nurses working
shifts around the clock (24/7).
The QI project participants consisted of six inpatient clients and 16 clinicians who were
members of the multidisciplinary team on two chronic care wards (A2 and C3). The clients'
selection and participation in the QI project were coordinated by the psychiatry clinician
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participants. Three clients with OUD were chosen from each of the assigned wards. The DNP
student was not directly involved with the clients at any time during the study.
The clinical staff inclusion criteria were based on their willingness and availability to participate
in the project, commitment to complete the pre-and post-intervention questionnaires, and team
participation. The criteria for exclusion included all staff that were not part of the treatment team,
those who worked on an off-hours shift. Similarly, clients 18 years and under were excluded
from the study as well as those that did not meet the DSM-V criteria for OUD.
Pre-Intervention
The plan for the project began in the fall of 2019 through a conversation with a
colleague and DNP student adviser about a DNP QI project. The DNP student then
proceeded to do a literature search on opioid abuse sentinel episodes at the identified facility
site before discussing them with the stakeholders. Also, the DNP student interviewed various
clinical personnel in the area about the problem of opioid abuse and overdose at the facility,
the disproportionate care, and how to improve treatment for psychiatric inpatient clients
suffering from OUD. The literature review identified evidence-based interventions that
could be implemented to improve treatment for psychiatric patients with OUD. A
PowerPoint training format on evidence-based opiate assessment scales was developed from
the literature review to provide training to healthcare clinicians on Wards A2 and C3 of the
project site.
A letter of support was obtained January 2020 after the key stakeholders who consisted
of the Facility Medical Director (FMD), the Chief Operating Officer, the Nursing Director,
and the Chief of Psychiatry endorsed the implementation of the QI project. The endorsement
of the project by these key stakeholders energized the multidisciplinary clinicians on Wards
A2 and C3 to participate in the QI performance.
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Other stakeholders involved in the project were administrative staff and unit managers who
assisted with dispensing the questionnaires and encouraged nursing staff and other participants to
use the screening scales when assessing clients. These teams of experts provided profound
contributions that led to the success of the project. As a result, numerous discussions were held
between the team and the DNP student to review the specifics concerning the QI project
planning.
The implementation of the project commenced in early November 2020. The DNP student
presented an overview of the project to the participants on Wards A2/C3 and administered the
pre-test survey prior to dispensing the educational training. The pre-test questionnaire (Appendix
I) was developed by the DNP student to obtain information from the multidisciplinary team
about their clinical strengths, weaknesses, and timely utilization of OUD screening scales during
the admission evaluation and at other times when opiate abuse is suspected of triggering a
change in a client’s mental status. The pre-test survey is a 5-point Likert type scale made up of
ten questions with the answer selections of 1) strongly disagree, 2) disagree, 3) uncertain, 4)
agree, and 5) strongly agree. Additionally, three of the pre-test questions address the screening
scales and participants’ comfort level with using the scales, 4 questions focused on opioid abuse
signs and symptoms and its negative effects on clients and 3 questions centered on evidencebased recommendations to use MAT, counseling, and substance awareness group to treat clients
with OUD. Moreover, the pre-test questionnaire was designed to illicit the knowledge and
thoughts of the multidisciplinary team regarding the relevance and benefits of the timely referral
of the identified OUD clients to treatment that consisted of MAT, individual counseling, and a
substance awareness group.
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Intervention
The education intervention involved one power point presentation delivered on two
separate units to the project participants at the psychiatric hospital through email. The
PowerPoint presentation (Appendix M) addressed opioid abuse signs and symptoms, introduced
the scales: Clinical Opiate Withdrawal Scale (COWS) and the Screening, Brief Intervention,
Referral to Treatment (SBIRT) and explained the need for early assessment with the screening
scales, provided training in the use of the scales, and addressed the referral of patients with OUD
to medication-assisted treatment, a substance awareness group, and individual counseling.
The presentation (Appendix M) included a thorough review of both the COWS and the
SBIRT tools, which included the following information: Clinical Opiate Withdrawal Scale
(COWS) is an 11-item tool designated for implementation by healthcare practitioners to assess
and monitor signs and symptoms of opiate withdrawal in inpatient and outpatient settings
(Tompkins et al., 2009). The COWS tool was assessed to have a Cronbach's alpha of 0.78,
indicating good internal consistency and reliability and a strong correlation rate of [r>0.5]
(Tompkins et al., 2009). Also, the SBIRT tool was given an excellent internal reliability scale
rate component (>85) and correlated validity rate[r=.45] (DiClemente et al., 2015). Additionally,
the Screening, Brief Intervention, and Referral to Treatment (SBIRT) tool is designed to provide
early intervention and treatment for individuals diagnosed with substance abuse or clients at risk
of displaying OUD (SAMHSA, 2017). Furthermore, copies of the screening scales were also
distributed through an email message to the project participants. Likewise, supplemental
materials on OUD signs and symptoms, and information on motivational interviewing were
posted on poster boards in the staff break room, conference room, nurses’ stations on the units,
and dining rooms.
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Following the presentation, clinicians were encouraged via email by this DNP student to
utilize the screening scales for OUD on Wards A2 and C3 at the project site from November
2020 to January 2021. The DNP student also engaged in discussions with the multidisciplinary
team to gather feedback on the pros/cons and their perception of the QI project. This information
was used to identify outliers during the implementation of the QI project evidence-based
intervention.
Client Referrals and Interview: One of the project’s goals were to improve opioid abuse
assessment, opioid abuse diagnosis, and the timely referral of identified clients to treatment and
then to monitor the clients' change process. Consequently, six clients were identified by the four
psychiatric clinicians for referral. They were referred to a treatment program that included MAT,
a substance awareness group, and counseling intervention that incorporated motivational
interviewing skills to spur patients along the stages of change trajectory.
The clinical staff participants were encouraged to utilize the TTM tenets of change in
monitoring their client's adherence to the MAT and psychotherapy intervention. The DNP
student collected qualitative data from case briefs on client’s behavior change with the
psychiatric clinicians centered on the patients’ compliance with specialty treatment. The
interview questions addressed the timely referral of the identified clients to MAT, the
commitment of the clients to MAT, their dedication to the substance awareness recovery group
and to counseling, and their trajectory of change based on the tenets of the TTM.
Post-Intervention
Post-test questionnaire (Appendix J), developed by the DNP student was administered to
all participants three months after implementing the evidence-based intervention to obtain
participant perception on the educational intervention. The post-test survey also comprised ten
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questions and had a 5-point Likert response of 1 to 5 like the variables answer choices in the pretest questionnaire. Two questions on the post-test questionnaire addressed the participants’
opinion about the educational intervention, 4 questions were asked to assess their confidence
level with the screening scales, 2 questions addressed OUD treatment and 2 questions focused on
consistency with using the scales. Overall, the post-test survey evaluated the participants’ view
on the education intervention, how often clinicians used the screening scales, their
comfortability/confidence level with using the scales, engagement of client in treatment
modalities and self-report of influence on client behavior change. Furthermore, the DNP student
dispensed the post-intervention evaluation questionnaire to gather data about the quality
improvement project implementation.
Data Analysis
Descriptive statistics were utilized to analyze the quantitative data from the
questionnaires. The mean and standard deviation of the responses from the pre-test and posttest questionnaires were calculated and organized on a Microsoft Excel spreadsheet
(Appendices K & L). Individual answers to questions were assessed for variations in
knowledge and graded on a percentage criterion. One hundred percent was the maximum
score, and zero percent was the lowest possible score. The difference between the pre and
post-test scores per participant was presented on a run chart. The interview data on case
briefs about the patient change in behavior related to adherence to MAT and the substance
awareness psychotherapy intervention and counseling were examined in themes for the
report. Tables 4 and 5 (Appendices K and L) contain the descriptive statistics of the pre-and
post-test scores in terms of percentages.
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Ethical Considerations/Protection of Human Subjects
Before implementing the project, the DNP student forwarded a human subject
determination form to the University of Massachusetts Amherst Human Research Protection
Office Internal Review Board (IRB) to obtain consent. The IRB reviewed the project and
decided that the project did not meet the federal regulatory definition of a human subject study
and therefore did not require approval from the IRB (Appendix D). Likewise, the project site did
not require IRB assent. Indeed, the members of the board were in full support of this project, as it
is a quality improvement project. A letter of support was also obtained from the project site
medical director.
The main goal of the QI project was to provide education about standardized opioid use
disorder assessment scales. It included assessing the consistent utilization of these tools and
implementing evidence-based, multifaceted recommendations based on the literature that
includes early referral to MAT, counseling, psychotherapy intervention for opioid abuse, and
monitoring clients with OUD through the stages of the behavior change trajectory. As stated
previously, the DNP student was not directly involved with the clients.
The data was gathered solely from the scores of the five-point Likert pre-intervention and
post-intervention questionnaires and open-ended case briefs interviews with clinicians about the
consistency with using these assessment scales and the client's compliance with treatment. The
DNP student did not have access to electronic information about the human subject sample. The
interview discussions with clinicians about the clients identified with OUD and treatment
modalities strictly adhered to the Health Insurance Portability and Accountability Act of 1996
(HIPAA) confidentiality standard and hospital laws and privacy procedures. The private
information of the participants was de-identified, and case numeric identification figures and
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letters were allocated to the clinicians and their clients as a replacement for initials during the
data storage process (Chevrier et al., 2019).
Results
The QI project for opioid use was implemented on two units of a 320-bed inpatient public
psychiatric hospital in western Massachusetts from November 2020 to January 2021. The
participants who implemented the intervention were mental health clinicians who were members
of the multidisciplinary treatment team and worked with patients with chronic psychiatric
disorders. The QI project participants consisted of psychiatry providers, psychologists, social
workers, occupational therapists, registered nurses, and a licensed mental health counselor. A
total of 20 participants were initially selected for the educational session and implementation of
the screening scales. However, only 16 (N=16) participants completed both pre and post-test
questionnaire and implemented the scales. In addition, four psychiatry clinician participants
attended the case brief interview sessions on monitoring and reporting the change process of six
patients with OUD. The number of participants that took the pre-test and post-test survey and the
classification of their various disciplines are presented in Table 1.
Table 1
Classification of the Disciplines of the Project Participants
Discipline

Participants

Percentage

Psychology

2

11.76%

Psychiatry

4

23.53%

Nursing

3

17.64%

OT/Rehab

1

5.88%

LMHC

1

5.88%
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Social Work

5

29.41%

Other

0

0.0%

Most of the participants who completed the questionnaires were non-nursing mental health
care clinicians. Of the 16 mental health care providers, 29.41% (n= 5) were licensed clinical
social workers, 23.53% (n= 4) were psychiatrists or psychiatric mental health nurse practitioners,
and 5.88% (n=1) were occupational/rehabilitation therapists. Similarly, 11.76% (n=2) of the
participants were psychologists and one was a licensed mental health counselor (5.88%). Of the
16 project participants, only 17.64% (n=3) were registered mental health nurses.
The data collected by the inquiry will be examined in the following sections, which are
illustrated by the descriptive statistics from Tables 4 and 5 (Appendices K and L). A run chart
was also used to compare the participants' responses to the pre and post-test questionnaires
(Figure 1, pg. 30).
The pre-test intervention questionnaire revealed a need for knowledge concerning
assessing, identifying, and managing clients with opioid abuse disorder. The pre-test
questionnaire's highest score was 94%, while the lowest score was 25% and the average score
was 50%. Only 31% (n= 5) of the participants exhibited confidence in using the screening scales.
From the 16 participants, only 25% (n=4) noted that they were familiar with opioid abuse signs
and symptoms. Eighty-one percent of the participants (n=13) indicated that they needed more
information about opioid abuse signs and symptoms. In comparison, 38% of the participants
(n=6) agreed they felt confident in their ability to use the screening scales. Fifty percent (n= 8) of
the participants agreed that they were comfortable with their knowledge of medication-assisted
treatment for OUD. In comparison, 38% (n=6) decided that it is essential to discuss such
treatment with their identified OUD clients before referring them to specialty treatment and 94%
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(n=15) agreed that they needed more information and education about opioid use disorder
screening scales.
The post-test questionnaire uncovered an increase in knowledge about opioid abuse signs
and symptoms and participants reported an increase in confidence in using the screening
scales to identify OUD clients and promptly referring patients to specialty treatment. The
highest score in the post-test questionnaire was 100% while the lowest score was 63%. The
average score was 88%. Ninety-four percent of the participants (n=15) agreed that
knowledge was gained from the educational presentation and 93.8% (n=15) indicated that
they were well informed about OUD signs and symptoms.
Similarly, 81.3% (n=13) agreed that their confidence to use the screening scales
increased after the PowerPoint presentation and 87.5% (n=14) indicated that they felt more
confident about engaging clients using SBIRT and counseling with motivational interviewing
techniques. Furthermore, 93.7% (n=15) agreed that the educational intervention increased
their knowledge about MAT, counseling, and substance awareness group, while 87.5%
(n=14) indicated that the project intervention enhanced their ability to provide counseling to
clients and facilitated prompt identification of OUD clients and referral process to treatment.
The lowest score in the post-test questionnaire was 63% (n=10) of participants who
agreed that they consistently used the screening scales to evaluate new intakes during the
admission process. One hundred percent of the participants (n=16) agreed that they
benefitted from the project intervention. However, 93.75% of the participants (n=15) agreed
that they would continue to use the information from the QI project to make changes in their
practice. Figure 1 shows the different scores for each participant in the pre and post-test
questionnaires.
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Figure 1
Comparison Between Pre and Post Test Scores per Participant
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The above data revealed a constructive improvement in the post-test score in all
participants. Additionally, most of the post-test questionnaire participants had scores > 80%
(n=15) of increase in test scores which means increased knowledge was obtained from the
education intervention. Likewise, the post-test participants more than doubled their scores.
Figure 1 illustrates comparison scores for each participant in the pre-test and post-test
questionnaires.
Results, Case Briefs on Behavior Change of Clients
The DNP student conducted two successful 15-minute individual case brief interview
sessions with four psychiatry clinicians on the multidisciplinary team to ascertain the
behavior change of the six clients as well as their progress in treatment. The interviews were
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conducted in January 2021 prior to the administration of the post-test survey. After meeting
with the psychiatry clinicians, the responses revealed encouraging results. The clinicians
described the impact of the educational intervention as successful, as evidenced by the
enrollment of four clients in medication-assisted treatment (MAT) and the remaining two
clients still waiting to start Buprenorphine treatment. Also, all six patients participated in a
substance awareness recovery group and counseling during the project implementation.
Furthermore, two clinicians noted a substantial change in the clients’ behavior due to
improved insight into the risk of opioid abuse and MAT. Moreover, it was mentioned that the
clients gained insight into their risky behavior through adherence to psychotherapy groups
and individual counseling from their psychiatry clinicians.
Therapy was also reported to have positive results in that, clinicians reported that
clients with access to both MAT and psychotherapy intervention for substance
awareness/counseling made drastic progress on the change trajectory based on the TTM. In
fact, according to the four psychiatry clinicians, MAT possibly contributed to the eradication
of complaints and craving for illicit opiates by the four clients who were engaged in MAT,
while the substance awareness and psychotherapy/counseling interventions helped the clients
develop insight into their previous risky behavior of abusing opiates. Most clinicians noted
that incidents of opioid abuse and overdose were significantly reduced by ninety percent
except for one incident during the implementation of the QI project on Wards A2 and C3, as
evidenced by reports from the daily rounds. In addition, all four clinicians agreed that the
patient participants were motivated to change. Four out of the six clients who participated in
the QI project stated that they will continue to engage in specialty treatment for OUD after
discharge from the inpatient facility.
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Discussion
The QI project for opioid use disorder took place on two units at a psychiatric hospital in
western Massachusetts. The QI project implementation provided multifaceted evidence-based
education to mental health professionals at the project site both by emailed presentations and in
person case debriefs. The goal of the QI project was to improve opioid abuse assessment,
diagnosis, and early referral of identified clients to treatment and to monitor the change process
of six patients who engaged in specialty treatment three months after the implementation of the
screening scales.
Through education, coaching, and early referral to specialty treatment, clinical providers can
enhance the quality of life of clients struggling with OUD (CDC, 2016). Prior to the PowerPoint
educational presentation, all participants completed a pre-test questionnaire to examine their
thoughts about OUD, the screening scales, and treatment that includes MAT, individual
counseling, and substance awareness groups. The results demonstrated that there was an
improvement in knowledge after the educational PowerPoint presentation.
The pre-test and post-test surveys had good participation, with 16 mental health care
providers completing them. Although the number of participants was small (n=16), the project
result was consistent with the literature regarding the benefits and sustainability of using OUD
screening scales such as the COWS and SBIRT to identify clients and prompt referrals for
specialty treatment. The finding from the review of the literature revealed that evidence-based
practice should include counseling with motivational interviewing skills, clinical judgment, and
easy access to MAT for patients with OUD (CDC, 2016).
The US Preventative Service Task Force [USPSTF] (2019) recommends opioid use
disorder treatment, which involves assessing the use of illicit drugs, the misuse of prescription
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drugs, and the subsequent referral for intervention to counteract drug abuse. Moreover, the
COWS is designated for clinicians to assess and monitor for signs and symptoms of opiate
withdrawal in inpatient and outpatient settings (Tompkins et al., 2009), and several studies
recognize the COWS as reliable (Wesson & Ling, 2003). Similarly, the SBIRT tool is designed
to address early intervention and treatment for individuals diagnosed with substance abuse or
clients at risk of displaying OUD (SAMHSA, 2017).
The intervention improved patient outcomes in the inpatient psychiatric hospital by
increasing the clinical team's knowledge to detect and empower clients to engage in specialty
treatment. Rosenthal et al. (2018) revealed a knowledge gap about clinicians’ comfortability with
using the COWS and SBIRT screening scales in assessing OUD clients in the inpatient setting.
This is in line with what the DNP student discovered during the implementation process. The
pre-test intervention questionnaire revealed a need for knowledge about assessing, identifying,
and managing clients with opioid abuse disorder. As previously mentioned, 31% (n= 5) of the
participants exhibited confidence in using the screening scales, 25% (n=4) noted that they were
familiar with opioid abuse signs and symptoms, and 81% of the participant (n=13) indicated that
they needed more information about opioid abuse signs and symptoms.
The post-test intervention questionnaire uncovered an increase in knowledge concerning
opioid abuse signs, symptoms, and confidence in using the screening tools to identify OUD
clients and the timely referral of patients to specialty treatment. Consequently, 100% (n=16) of
the post-test participants agreed that their clinical practice and patients benefitted from the
educational presentation and the implementation of the screening scales. As a result of the
educational intervention and implementation, six clients with OUD were appropriately identified
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and referred to medication-assisted treatment, counseling and completed the substance awareness
recovery group.
In addition, the four identified clients were educated by their clinicians about the risk of
opioid abuse and the benefits of engaging in specialty treatment that can lead to optimal
wellbeing. The clients' change process was initiated and evaluated by the mental health providers
through the transtheoretical model (TTM) of behavior change. Prochaska et al. (1992) noted
people's intentionality in the changing paradigm. The study authors also noted that individuals
were observed as advancing linearly through the stages of pre-contemplation, contemplation,
preparation, action, and maintenance before termination. The TTM demonstrates an
understanding of when shifts in the opinions and objectives of clients occur (Prochaska et al.,
1992). In this way, the clinicians at the project site expressed that they observed their clients'
shifts in attitude and behavior as indicated by the TTM as they engaged in specialty treatment.
The project participants reported that they will continue to use the knowledge from the
educational intervention and the OUD screening scales in their clinical practice. Most of the
providers noted that opioid abuse and overdoses were significantly reduced during the QI project
implementation on Wards A2 and C3 at the project site. Also, the post-test questionnaire scores
demonstrated knowledge gained in that 100% (n=16) of the participants agreed that they
benefitted from the educational intervention and implementation of the scales. The interview
data from the clinicians about their clients indicated that the implementation of the screening
scales aided the identification of clients during intake assessment with OUD and fostered a
timely referral to specialty treatment.
The strengths of the QI project included the support of the stakeholders and
multidisciplinary team members on Wards A2 and C3. Additional strengths were access to
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providers with prescription authority, access to counseling and psychological resources, and
access to available materials that can be used by providers, patients, and the community to
expedite education.
A significant barrier during the implementation of the QI project implementation was the
Covid-19 pandemic and the surge of positive cases of infection at the project site. As a result, the
facility administration established restrictive protective policies that increased the DNP student's
timeframe at the project site due to the participants’ absentee rate either from being sick from the
virus or quarantining at home after exposure to the virus. Likewise, due to the coronavirus
pandemic, very few patients were admitted or transferred from other facilities. Thus, 62.5% of
the participants (n=10) agreed in the post-test survey that they could not consistently use the
OUD screening scales in their clinical assessment of patients. However, 93.75% of the
participants (n=15) agreed that they would continue to use the information from the QI project to
make changes in their practice. Both clinician and client participants expressed that the QI
project was successful, and several clinicians expressed a plan to integrate the knowledge gained
into their clinical practice.
Implications and Recommendations
This project emphasized the importance of addressing a specific patient population within the
psychiatric hospital setting. Velez et al. (2016) concisely concluded that inpatient hospitalization
is an appropriate timeframe to successfully reach patients who are indicated for substance abuse
treatment, as they may comprehend that substance abuse has harmfully affected their wellbeing.
According to the USPSTF (2019), the recommendation for opioid use disorder (OUD) treatment
involves assessing the patient for the use of illicit drugs and the misuse of prescription drugs and
providing referral for intervention to counteract drug abuse. The QI project implemented opioid

36
abuse scales to identify and refer patients with OUD to MAT and monitor behavior change with
the tenets of the transtheoretical model (TTM). The TTM is an essential deliberate framework
for monitoring improvement in behavior change, especially in addiction treatment. The clinical
providers explored the tenets obtained from the model to monitor behavior change and practice
improvement successfully. As indicated by the data collected in the case brief interviews with
clinicians, the patient participants were motivated to change.
The significance of additional study into the occurrence of OUD and appropriate utilization
of the screening scales to promptly identify and refer clients within a facility for treatment is
essential. Educating clinical providers on an ongoing basis to properly assess, diagnose, and refer
psychiatric clients with OUD to specialty treatment that includes medication-assisted treatment,
counseling, and a substance awareness group is crucial to reducing hospitalization. The QI
project was implemented successfully on two units in a psychiatric hospital. It is recommended
that the findings of the project be extrapolated to other wards in the facility. Van Hoeven et al.
(2015) expressed that a predetermined diminutive sample size can be utilized to represent a large
target population. Similarly, the screening scales should be included in the electronic health
record intervention to be completed by healthcare providers for all clients during admission
evaluation. Also, efforts should be made on an ongoing basis to ensure that psychiatric facilities
incorporate current evidence-based treatments and modalities to manage clients with OUD
better.
Conclusion
The timely evaluation and treatment of patients with OUD at a psychiatric hospital are
essential. The evidence-based literature shows that a combination of early assessment to identify
clients with OUD, medication, and psychotherapy intervention can successfully treat patients
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struggling with OUD (SAMHSA, 2021). Velez et al. (2016) concluded that inpatient
hospitalization is an appropriate timeframe to successfully reach patients who are indicated for
substance abuse treatment, as they may comprehend that substance abuse has negatively affected
their wellbeing. Hence, appropriate assessment/treatment should be addressed and initiated
concurrently in the inpatient hospital setting. Evidence-based findings from the literature review
revealed that a multifaceted intervention approach that consists of appropriate assessment with
standardized OUD tools, early referral to medication-assisted treatment, counseling, and
psychotherapy intervention for substance awareness is needed to combat the opioid abuse crisis.
Consequently, the QI project implemented a comprehensive, evidence-based clinical
intervention to improve the assessment, diagnosis, and treatment of adult patients suffering from
OUD in the inpatient psychiatric hospital setting. This project's findings substantiate an overall
increase in the knowledge of how to enhance the care of hospitalized psychiatric patients
suffering from OUD. The implementation of the QI project improved the clinical skills of the
multidisciplinary team members regarding how to use the screening scales to identify clients
with OUD to enhance the process of the referral of patients to specialty treatment. In addition,
the QI project facilitated the patients’ knowledge about the risk of opioid abuse and the need to
remain in specialty treatment within the hospital and after discharge.
The project positively impacts the facility regarding managing patients with OUD in an
inpatient psychiatric hospital setting. This project emphasizes the importance of addressing a
specific patient population within the psychiatric hospital setting. Further study needs to be
conducted to find ways to tackle the needs of patients with co-occurring mental illness and OUD.
However, the project's findings could help increase measures to manage inpatient psychiatric
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clients suffering from OUD and reduce emergency department evaluation/treatment, unforeseen
hospitalizations due to overdose from opioids, and readmissions.
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Appendices
Appendix A
Figure 2: Stages of Change

Note: The Transtheoretical Model (TTM) of Behavior Change (Prochaska & Diclemente, 1982)
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Appendix B
Table 2
Itemized Details of Cost-Benefit
Items

Cost in Dollars

Copy and printing paper for survey, training session,
40.00
handouts
Toner cartridge for printer

40.00

Office supplies: Pack of pens, folders

20.00

Conference room allocated for training session,
0.00 (provided by facility)
office space and bill
Clinical staff

0.00 (provided by facility)

Laptop

00.00 (provided by DNP student)

Time for staff training

00.00

Light refreshment pre-Covid19 pandemic surge

100.00

Total cost for quality improvement project

200.00
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Table 2
Itemized Details of QI Project Timeline
Timeline

Itemized Details of QI Project
Following approval of proposal.
Provide details of the DNP QI proposal to

Week 1

facility stakeholders and obtain a letter of
support.
Provide an overview of the QI project proposal

Week 2

to clinical personnel on ward A2 and C3 and
administer the pre-test questionnaires.
Provide training sessions on COWS and SBIRT

Week 3

and implement the screening toolkits in assessing
patients for OUD during intake evaluation.
Monitor a consistency in implementing COWS

Weeks 4 – 11

and SBIRT and referral of patients to MAT and
substance abuse groups
Conduct 1:1 interview with clinical personal to

Week 9

evaluate stages of behavior change among clients
with OUD
Conduct 1:1 interview with clinical personal to

Week 10

evaluate stages of behavior change among clients
with OUD
Conduct 1:1 interview with clinicians to evaluate

Week 11

compliance with MAT/psychotherapy
intervention

Week 12

Administer post-intervention questionnaires
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Appendix D
IRB Approval Letter
Mass Venture Center
100 Venture Way, Suite 116
Hadley, MA 01035
Telephone: 413-545-3428

Memorandum – Not Human Subjects Research Determination

Date: November 6, 2020
To: Pauline Eteng, College of Nursing
Project Title: A performance Improvement Project for Opioid Abuse Disorder on a Chronic Care
Psychiatric Hospital in Western MA
HRPO Determination Number: 20-235
The Human Research Protection Office (HRPO) has evaluated the above named project and has made
the following determination based on the information provided to our office:
☐ The proposed project does not involve research that obtains information about living individuals
[45 CFR 46.102(f)].
☐ The proposed project does not involve intervention or interaction with individuals OR does not use
identifiable private information [45 CFR 46.102(f)(1), (2)].
☒ The proposed project does not meet the definition of human subject research under federal regulations
[45 CFR 46.102(d)].
Submission of an Application to UMass Amherst IRB is not required.
Note: This determination applies only to the activities described in the submission. If there are changes
to the activities described in this submission, please submit a new determination form to the HRPO prior
to initiating any changes. Researchers should NOT include contact information for the UMass
Amherst IRB on any project materials.
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A project determined as “Not Human Subjects Research,” must still be conducted ethically. The UMass
Amherst HRPO strongly expects project personnel to:
-

treat participants with respect at all times
ensure project participation is voluntary and confidentiality is maintained (when applicable)
minimize any risks associated with participation in the project
conduct the project in compliance with all applicable federal, state, and local regulations as well
as UMass Amherst policies and procedures, which may include obtaining approval of your
activities from other institutions or entities.

Please do not hesitate to call us at 413-545-3428 or email humansubjects@ora.umass.edu if you have
any questions.

Iris L. Jenkins, Assistant Director
Human Research Protection Office
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Appendix E
Clinical Opiate Withdrawal Scale (COWS)
Flowsheet for measuring symptoms for opiate withdrawals over a period
For each item, write in the number that best describes the patient’s signs or symptoms. Rate on
just the apparent relationship to opiate withdrawal. For example, if the heart rate is increased
because the patient was jogging just prior to assessment, the increased pulse rate would not add
to the score.

Patient’s Name:
Date:
Enter scores at time zero, 30min after first dose, 2 h after first dose, etc.
Times:

Resting Pulse Rate: (record beats per minute)
Measured after patient is sitting or lying for one minute
1 pulse rate 80 or below
2 pulse rate 81-100
3 pulse rate 101-120
4 pulse rates greater than 120
Sweating: over the past ½ hour not accounted for by room
temperature or patient activity.
1 no report of chills or flushing
2 subjective report of chills or flushing
3 flushed or observable moistness on face 3 beads of
sweat on brow or face
4 sweat streaming off face
Restlessness Observation during assessment 0 able to
sit still
1 reports difficulty sitting still, but is able to do so
3 frequent shifting or extraneous movements of legs/arms 5 Unable to
sit still for more than a few seconds
Pupil size
1 pupils pinned or normal size for room light
2 pupils possibly larger than normal for room light 2 pupils
moderately dilated
5 pupils so dilated that only the rim of the iris is visible
Bone or Joint aches If patient was having pain previously, only the
additional component attributed to opiates withdrawal is scored
1 not present
2 mild diffuse discomfort
3 patient reports severe diffuse aching of joints/ muscles 4 patient is
rubbing joints or muscles and is unable to sit
still because of discomfort
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Runny nose or tearing Not accounted for by cold symptoms
or allergies
1 not present
2 nasal stuffiness or unusually moist eyes 2 nose
running or tearing
4 nose constantly running or tears streaming down cheeks
GI Upset: over last ½ hour
0 no GI symptoms 1 stomach
cramps
2 nausea or loose stool 3 vomiting
or diarrhea
5 Multiple episodes of diarrhea or vomiting
Tremor observation of outstretched hands
1 No tremor
2 tremor can be felt, but not observed 2 slight
tremor observable
4 gross tremor or muscle twitching
Yawning Observation during assessment
1 no yawning
2 yawning once or twice during assessment
3 yawning three or more times during assessment 4 yawning
several times/minute
Anxiety or Irritability
1 none
2 patient reports increasing irritability or anxiousness 2 patient
obviously irritable anxious
4 patient so irritable or anxious that participation in the assessment is
difficult
Gooseflesh skin
0 skin is smooth
3 piloerections of skin can be felt or hairs standing up on arms
5 prominent piloerections

Total scores with observer’s initials

Score:
5-12 = mild
13-24 = moderate
25-36 = moderately severe
more than 36 = severe withdrawal

Source: Wesson & Ling (2003)
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Appendix F
Figure 3: Screening, Brief Intervention, and Referral to Treatment (SBIRT) Scale

Note: Flow Chart of Screening, Brief Intervention, and Referral to Treatment (SBIRT) in
Practice (Wright et al., 2016).
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Appendix G
Figure 4: Motivational Interviewing Technique

Note: Motivational Interviewing: Helping People Change (Miller & Rollnick, 2013).
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Appendix H
Figure 5: What is SBIRT

Note: What is SBIRT? An Early Intervention Approach (Indiana University, 2013)
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Appendix I
Pre-Test Questionnaire
Participants’ Initials:
Please select only one of the appropriate responses that best explain your thoughts on the choices
below.
1. I feel confident in my abilities to use the Clinical opiate withdrawal scale in evaluating
my clients during admission.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

4
Agree

5
Strongly Agree

2. I am familiar with opiate overdose signs and symptoms.
1
Strongly Disagree

2
Disagree

3
Uncertain

3. I need more information about opiate overdose signs and symptoms.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

4. I am aware that opioid abuse can negatively impact a patient’s health and lead to
overdose and death.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

5. I feel confident in my ability to use the screening, brief intervention, and referral to
treatment toolkit during intake assessment and when clients exhibit a change in mental
status related to opioid abuse.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

6. I feel confident in my abilities to do brief intervention counseling about opioid abuse
during intake assessment and at other times to identify clients with opioid abuse in order
to refer them for treatment.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree
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7. I am aware of evidence-based recommendation procedures to treat patients with opioid
use disorder.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

8. I feel comfortable in my knowledge about medication assisted treatment for opioid use
disorder.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

9. When a client is assessed as meeting criteria for opioid use disorder according to DMS-V
stipulations; I think it is important to discuss with them prior to referring them to 12 step
meetings, SMART program or DBT for substance awareness.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree

10. I need more information and education about opioid use disorder toolkits.
1
Strongly Disagree

2
Disagree

3
Uncertain

4
Agree

5
Strongly Agree
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Appendix J
Post-Test Questionnaire
Participants’ Initials:
Please select only one of the appropriate responses that best explain your thoughts on the choices
below.
1. I feel that I learned from the PowerPoint presentation on opioid use disorder toolkit.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

2. I am well informed about opioid overdose signs and symptoms.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

3. I have been using the toolkits for intake assessment and for patients that exhibit mental
status changes in the milieu after the PowerPoint presentation session
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

4. My confidence to use the toolkit to assess clients with opioid use disorder increased after
the educational session.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

5. After participating in this QI project, I feel more confident about my ability to engage
clients for brief counseling with motivational interviewing skills
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1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

6. Participating in this project increased my knowledge about medication-assisted
treatment and psychotherapy intervention.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

7. Participating in this project increased my ability to provide brief counseling about the
dangers of opioid abuse prior to referring identified clients to specialty treatment.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

8. I have consistently used the opioid use disorder toolkit in my clinical assessment after
attending the educational presentation sessions.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

9. I feel that my clinical practice and patients benefited from the educational
presentation.
1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree

10. I will continue to use the information from the performance improvement project to
make changes in my clinical practice.
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1

2

3

4

5

Strongly
Disagree

Disagree

Uncertain

Agree

Strongly Agree
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Appendix K
Table 4
Descriptive Statistics of Pre-Test Scores for Opioid Abuse and Opioid Screening Knowledge
Areas (N=16)
Number

Mean

Std
Deviation

Percentages

5

0.31

0.48

31.25%

4

0.25

0.45

25%

I need more information about opiate overdose signs
and symptoms.

13

0.81

0.40

81.25%

I am aware that opioid abuse can negatively impact a
patient's health and lead to overdose and death.

14

0.88

0.34

87.5%

0.38

0.50

37.5%

7

0.44

0.51

43.75

I am aware of evidence-based recommendation
procedures to treat patients with opioid use disorder.

10

0.62

0.50

62.5%

I feel comfortable in my knowledge about medicationassisted treatment for opioid use disorder.

8

0.50

0.51

50%

6

0.38

0.50

37.5%

15

0.94

0.25

93.75%

I feel confident in my abilities to use the Clinical
opiate withdrawal scale in evaluating my clients
during admission.
I am familiar with opiate overdose signs and
symptoms.

I feel confident in my ability to use the screening, brief
6
intervention, and referral to treatment toolkit during
intake assessment and when clients exhibit a change in
mental status related to opioid abuse.
I feel confident in my abilities to do brief intervention
counseling about opioid abuse during intake
assessment and at other times to identify clients with
opioid abuse to refer them for treatment.

According to DMS-V stipulations, when a client is
assessed as meeting criteria for opioid use disorder, I
think it is essential to discuss with them prior to
referring them to 12 step meetings, SMART program,
or DBT for substance awareness.
I need more information and education about opioid
use disorder scales.
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Appendix L
Table 5
Descriptive Statistics of Post-Test Scores for Opioid Abuse and Opioid Screening Knowledge
Areas (N= 16)

I feel that I learned from the PowerPoint
presentation on the opioid use disorder scales.
I am well informed about opioid overdose signs and
symptoms.
I have been using the toolkits for intake assessment
and patients who exhibit mental status changes in
the milieu after the PowerPoint presentation session.
My confidence to use the toolkit to assess clients
with opioid use disorder increased after the
educational session.
After participating in this QI project, I feel more
confident about engaging the clients for brief
counseling with motivational interviewing skills.
Participating in this project increased my knowledge
about medication-assisted treatment and
psychotherapy intervention.
Participating in this project increased my ability to
provide brief counseling about the dangers of opioid
abuse before referring identified clients to specialty
treatment.
I have consistently used the opioid use disorder
toolkit in my clinical assessment after attending the
educational presentation sessions.
I feel that my clinical practice and patients benefited
from the educational presentation.
I will continue to use the quality improvement
project's information to make changes in my clinical
practice.

Number

Mean

Std
Deviation

Percentages

15

0.94

0.25

93.75%

15

0.94

0.25

93.75%

13

0.81

0.40

81.25%

13

0.81

0.40

81.25%

14

0.88

0.34

87.5%

15

0.94

0.25

93.75%

14

0.88

0.34

87.5%

10

0.62

0.50

62.5%

16

1.00

0.00

100%

15

0.94

0.25

93.75%
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Appendix M
Opioid Use Disorder Education PowerPoint
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